The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.25
Bid: 35.00
Ask: 35.50
Change: 0.55 (1.58%)
Spread: 0.50 (1.429%)
Open: 34.75
High: 35.50
Low: 35.25
Prev. Close: 34.75
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal

18 Jan 2010 07:00

RNS Number : 6804F
China Real Estate Opportunities PLC
18 January 2010
 



China Real Estate Opportunities plc

Disposal of Tangdao Bay investment at 10.9% premium to independent valuation

China Real Estate Opportunities plc ("CREO" or the "Company"), an AIM listed property company with an established investment and development property portfolio in China, today announces that it has executed an unconditional contract to dispose of its 50% interest in the Tangdao Bay joint venture development. 

CREO's 50% interest in the joint venture has been sold to its partner in the project, SIIC Shanghai Holdings Company ("SIIC"). The sale price was based on a property value of RMB1.389bn representing a 10.9% premium to the most recent independent valuation in June 2009. Net cash proceeds from the transaction amount to £33.8 million at today's exchange rates with no borrowings to be repaid from the sale proceeds and will be received upon the completion of the standard PRC regulatory procedures for the offshore repatriation of proceeds of domestic asset sales.

The sale price reinforces CREO's reported NAV, and follows on from the June 2009 disposal of CREO's interest in the City Centre 5 development at an 8.9% premium to the independent valuation of 31 December 2008.

Furthermore the Company announces that due to the contracted disposal of Tangdao Bay, it has decided not to proceed with the issuance of zero dividend preference shares. In November 2009 the Company announced it was considering such an issuance to facilitate the repurchase of the Company's own ordinary shares which are trading at a significant discount to net asset value. Accordingly the Company proposes to commit up to £15 million from its cash resources to fund a tender offer for its own shares upon receipt of the Tangdao Bay sale proceeds.

At the same time the Company continues to work with its advisers to generate third party demand for its shares.

Commenting, Ray HorneyCREO Chairman said: "The CREO Board is very pleased to announce the execution of an unconditional contract for the disposal of its 50% ownership of the Tangdao Bay development, reinforcing the strength of CREO's balance sheet and underpinning its published net asset value as this sale represents the second asset disposal in the past 6 months above independent valuation. This transaction reinforces the Company's strategy of focussing on its core investment and development assets, particularly in Shanghai, and will further strengthen the Company's cash position and provide a strong platform for the Company to move forward in 2010 and beyond." 

"This sale is timely and as such it is appropriate for the Company to cancel the zero dividend preference share issue and propose the allocation of a prudent sum from its own cash reserves to underwrite its earlier commitment to a repurchase of the Company's own shares."

ENDS

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

Sarah Moriarty, Investor Relations 

Tel: +353 1 6189455

Matrix Corporate CapitalPaul Fincham, Rob Naylor Tel +44 (0)20 3206 7175

Davy

Des Carville

Tel: +353 1 679 6363

Citigate Dewe Rogerson Limited

Tom Baldock

Tel: + 44 (0) 20 7638 9571

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISDBGDBISBBGGR
Date   Source Headline
13th May 20247:00 amRNSDirectorate Changes
7th May 20247:00 amRNSCreo Medical receives King’s Award for Enterprise
25th Apr 20247:00 amRNSNotice of Results
24th Apr 20247:00 amRNSNHS Speedboat data demonstrates savings
20th Mar 20244:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSWelsh Labour Leader visits Creo’s facilities
13th Mar 20243:05 pmRNSHolding(s) in Company
11th Mar 20242:00 pmRNSLTIP Awards
6th Mar 20244:35 pmRNSHolding(s) in Company
1st Mar 20247:00 amRNSMicrowave Lung Ablation Update
7th Feb 20249:12 amRNSTrading Update - Replacement
7th Feb 20247:00 amRNSTrading Update
5th Feb 20247:00 amRNSStrategic Collaboration with Khalifa University
31st Jan 20247:00 amRNSSpeedboat® UltraSlim roll-out reaches Asia Pacific
22nd Jan 20247:00 amRNSAward of Shares under Share Incentive Plan
10th Jan 20247:00 amRNSFirst use of Speedboat® UltraSlim in Latin America
15th Dec 20237:00 amRNSFirst use of Speedboat® UltraSlim in the USA
13th Dec 20237:00 amRNSFirst European Speedboat® UltraSlim procedure
7th Nov 20237:00 amRNSCapital Markets Day
1st Nov 20237:00 amRNSSpeedboat® UltraSlim: US FDA Clearance
25th Oct 20237:00 amRNSSB UltraSlim: EU launch accelerated by 18 months
16th Oct 202310:16 amRNSChange of Nominated Adviser and Joint Broker
12th Oct 20237:00 amRNSInvestor Presentation
12th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSNotice of Results
16th Aug 20237:00 amRNSRoyal Oldham SSD service update
3rd Aug 20237:00 amRNSHalf Year Trading Update
28th Jul 20237:00 amRNSTotal Voting Rights
24th Jul 202310:40 amRNSAward of Shares under Share Incentive Plan
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.